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http://dx.doi.org/10.1016/j.ccell.2015.04.001SUMMARYLKB1 regulates both cell growth and energy metabolism. It remains unclear how LKB1 inactivation
coordinates tumor progression with metabolic adaptation in non-small cell lung cancer (NSCLC). Here in
KrasG12D;Lkb1lox/lox (KL) mouse model, we reveal differential reactive oxygen species (ROS) levels in lung
adenocarcinoma (ADC) and squamous cell carcinoma (SCC). ROS can modulate ADC-to-SCC transdifferen-
tiation (AST). Further, pentose phosphate pathway deregulation and impaired fatty acid oxidation collectively
contribute to the redox imbalance and functionally affect AST. Similar tumor and redox heterogeneity also
exist in human NSCLC with LKB1 inactivation. In preclinical trials toward metabolic stress, certain KL ADC
can develop drug resistance through squamous transdifferentiation. This study uncovers critical redox
control of tumor plasticity that may affect therapeutic response in NSCLC.INTRODUCTION
Non-small cell lung cancer (NSCLC) is marked by genetic and
histopathological heterogeneity (Heist and Engelman, 2012).
LKB1-mutant NSCLC represents a unique and prevalent molec-
ular subtype with limited treatment options (Govindan et al.,
2012; Imielinski et al., 2012; Kim et al., 2013). LKB1 mutation
has been detected in NSCLC subtypes including adenocarci-
noma (ADC), squamous cell carcinoma (SCC), and adeno-squa-
mous cell carcinoma (Ad-SCC) (Ji et al., 2007). In preclinical orSignificance
LKB1-mutant tumor represents a unique and prevalent mol
Through integrative human lung cancer sample analysis andmo
the accumulation of ROS during ADC progression, which mod
tiation and metabolic adaptation. This metabolic adaptation re
early lung ADC progression and an essential metabolic regulat
plasticity for squamous transdifferentiation enables ADC to pro
treatment toward cancer metabolism. The plasticity represents
bolic adaptation and drug resistance and holds important the
698 Cancer Cell 27, 698–711, May 11, 2015 ª2015 Elsevier Inc.co-clinical trials on genetically engineered mouse models
(GEMMs), Lkb1-deficient lung tumors show primary resistance
to treatments that are effective to KrasG12D mutant (Kras) or
KrasG12D;Trp53lox/lox (KP) mutant lung tumors (Chen et al.,
2012; Shimamura et al., 2013). LKB1 is therefore considered
as a genetic modifier of therapeutic response in NSCLC, but
the underlying mechanisms are not fully understood.
Originally characterized as a tumor suppressor, LKB1 phos-
phorylates and activates several downstream targets to inhibit
cell growth. Consequently, inactivation of LKB1 promotesecular subtype of NSCLC with limited treatment options.
deling tumor development in amousemodel, we uncovered
ulates the phenotypic transition as squamous transdifferen-
flects the dynamic function of LKB1: a tumor suppressor at
or at late phenotypic transition. The redox-controlled tumor
gress under stress, and more importantly to escape certain
as a potentially important mechanism for lung cancer meta-
rapeutic implications.
mTORC1 signaling and other progrowth pathways (Alessi et al.,
2006; Shackelford and Shaw, 2009). LKB1 also regulates cellular
energy sensing and metabolic homeostasis (Hardie, 2013). Inac-
tivation of Lkb1 in hematopoietic stem cells results in mitochon-
drial dysfunction and deregulated bioenergetics largely through
AMPK-independent mechanisms (Gan et al., 2010; Gurumurthy
et al., 2010; Nakada et al., 2010). The LKB1 substrate AMPK
promotes tumor cell survival under energy stress by regulating
NADPH homeostasis, whereas LKB1-deficient tumor cells are
sensitive to stress conditions such as glucose deprivation or
matrix detachment (Jeon et al., 2012). Although Lkb1-deficient
cells are resistant to oncogenic transformation and tumorigen-
esis in vivo (Bardeesy et al., 2002), inactivation of Lkb1 in
KrasG12D;Lkb1lox/lox (KL) NSCLC mouse model dramatically
accelerates lung tumor progression (Ji et al., 2007). This raises
an interesting question about how LKB1 inactivation coordinates
in vivo lung tumor progression with metabolic adaptation.
Notably, Lkb1 inactivation in KL model leads to expanded lung
tumor heterogeneity as indicated by the emergence of ADC,
SCC, and mixed Ad-SCC, a phenotype not observed in Kras
and KP models (Ji et al., 2007). We have shown recently that
the KL lung tumor heterogeneity results from p63-mediated
ADC to SCC transdifferentiation (AST) through mixed Ad-SCC
at late stage (Han et al., 2014). Consistently, expression of onco-
genic KRAS together with LKB1 downregulation in human
bronchial epithelial cells can efficiently drive tumorigenesis and
heterogeneity by producing SCC and Ad-SCC in nude mice
(Kim et al., 2013). These studies collectively have revealed unex-
pected plasticity upon LKB1 inactivation in NSCLC. However, it
remains unclear how LKB1 inactivation coordinates tumor pro-
gression with metabolic adaptation in orchestrating this tumor
plasticity.
RESULTS
Redox Heterogeneity Correlates with Lung Tumor
Heterogeneity in KL Model
Studies using both clinical samples and GEMMs suggest that
TTF1 and p63 are histologic markers distinguishing lung ADC
(TTF1+p63-) from SCC (TTF1p63+) (Mukhopadhyay et al.,
2014; Rekhtman et al., 2011; Xu et al., 2014). It was recently
demonstrated that inactivation of Lkb1 and Pten in Lkb1lox/lox;
Ptenlox/lox (LP) model can promote de novo SCC progression
from basal cells, and the SCC expressed p63 but not TTF1
(p63+TTF1) (Xu et al., 2014). Using TTF1 and p63 as bio-
markers, we characterized lung tumors from KL, Kras and KP
mouse models. Consistent with previous studies (Farago
et al., 2012), Kras or KP mice only developed TTF1+ ADC
that was negative for p63 (data not shown). Interestingly, while
KL ADC appeared TTF1+p63, early KL SCC (8–10 weeks post
Ad-Cre infection) and the squamous components of KL
Ad-SCC expressed both p63 and TTF1 (p63+TTF1+) (Figures
S1A and S1B); we observed about 18% of p63+ KL SCC with
low or even undetectable TTF1 expression only at the late
stage (12–14 weeks post Ad-Cre infection) (Figures S1B and
S1C). These results distinguished the SCC in KL model from
that in LP model, and supported a recently described AST pro-
cess, a phenotype not observed in either Kras or KP model
(Han et al., 2014). These observations also suggest that thepresence of p63+TTF1+ SCC may reflect the dynamic transdif-
ferentiation process and serve as an indicator for AST in the KL
model.
Using the gene expression profiles established previously
(GSE6135) (Ji et al., 2007), we performed gene set enrichment
analysis (GSEA) to identify the gene sets significantly enriched
in KL ADC or SCC (Tables S1 and S2). Interestingly, gene sets
of glutathione (GSH) metabolism, pyrimidine metabolism,
purine metabolism, or steroid biosynthesis were found signifi-
cantly enriched in SCC (Figure 1A and Table S1). GSH plays
indispensable roles in cellular redox homeostasis by promoting
reactive oxygen species (ROS) clearance, whereas GSH defi-
ciency leads to ROS accumulation and oxidative stress (Wu
et al., 2004). Quantitative real-time PCR (qRT-PCR) analysis
confirmed that KL SCC expressed higher levels of signature
genes for GSH synthesis (Gclm, Gsta4, Gstya1, and Gsto1)
and antioxidant process (Nqo1 and Gpx2) (Figure 1B). We per-
formed immunohistochemistry (IHC) to compare expression of
NQO1, the prototypical target of antioxidant transcription factor
NFE2-related factor 2 (NRF2) (Sporn and Liby, 2012). Indeed,
the SCC had much higher level of NQO1 than ADC (Figure 1C).
Consistently, 8-hydroxydeoxyguanosine (8-oxo-dGuo), a
marker of DNA oxidative modification by ROS (DeNicola
et al., 2011), showed significantly lower immunoreactivity in
SCC than in ADC (Figure 1D). Through liquid chromatog-
raphy-tandem mass spectrometry (LC-MS) analysis, we further
found that the SCC had higher GSH and ATP levels than ADC
(Figure 1E). Moreover, the SCC not only had higher lactate level
and lower glucose level (Figure S1D), but also expressed higher
levels of glycolytic enzymes, such as hexokinase 2 (HK2) and
lactate dehydrogenase A (LDHA) (Figures S1E and S1F).
Together, these results revealed the differential redox and
metabolic signatures in ADC and SCC of KL model. Kras and
KP mice, two non-KL models, only developed ADC but not
SCC (Farago et al., 2012). We previously showed that deletion
of Trp53 dramatically promotes ADC progression but not squa-
mous transdifferentiation in KP model (Han et al., 2014; Ji et al.,
2007). To verify whether ROS accumulation is specific to KL
ADC, we compared ROS-related signatures between KL ADC
and KP ADC. We found that KP ADC was enriched for gene
sets of cellular metabolism including GSH metabolism (Table
S3 and Figure S1G), and had less oxidative stress than KL
ADC (Figure S1H). Consistently, KP ADC also expressed higher
levels of NRF2 and NQO1 than KL ADC (Figure S1I), further
supporting less oxidative stress. These results collectively sug-
gest that the aberrant ROS accumulation is relatively specific to
ADC of KL model.
Redox and Tumor Heterogeneity in Human NSCLC with
LKB1 Deficiency
We performed IHC to compare LKB1 expression level with
8-oxo-dGuo level in tissue microarrays (TMAs) containing
162 human lung ADC specimens (Figure S2A). Interestingly,
LKB1 expression was significantly and inversely correlated
with 8-oxo-dGuo level in these ADC specimens (Figure S2B).
Importantly, about 40% (65/162) of human ADC showed
negative LKB1 expression and high 8-oxo-dGuo level (Fig-
ure S2B). Only among the 65 LKB1negative 8-oxo-dGuohigh
ADC specimens, we found 12.3% (8/65) with expression ofCancer Cell 27, 698–711, May 11, 2015 ª2015 Elsevier Inc. 699
Figure 1. Differential ROS Accumulation in
Lung ADC and SCC of KL Model
(A) GSEA plot of the GSH metabolism pathway
between KL ADC and SCC.
(B) Relative mRNA levels of signature genes for
GSH metabolism in KL ADC (n = 4) and SCC
(n = 4). Data are shown asmean ± SEM. **p < 0.01,
*p < 0.05.
(C) Left: H&E staining, p63, and NQO1 IHC staining
of KL ADC and SCC serial sections. Scale bar
represents 50 mm. Right: statistical analysis of
NQO1 IHC staining results.
(D) IHC staining and statistical analysis of 8-oxo-
dGuo+ cells in KL ADC and SCC. Scale bar rep-
resents 50 mm. Data are shown as mean ± SEM.
***p < 0.001.
(E) GSH and ATP levels in KL ADC (n = 6) and SCC
(n = 4) by LC-MS analysis. Data are shown as
mean ± SEM. ***p < 0.001, **p < 0.01.
See also Figure S1 and Tables S1–S3.SCC signature markers, such as p63, keratin (K) 5, and K14
(Figures 2A and S2C). Consistently, in six lung ADC with
LKB1-inactivating mutations (Gao et al., 2010a), two were
found with small lesions expressing SCC signature markers
(Figures 2B and S2D). Further analyses revealed that the
p63+ lesions in these ADC tended to have lower 8-oxo-dGuo
level and higher NRF2 and NQO1 levels than TTF1+ lesions
(Figure S2E).
Our IHC analyses further revealed heterogeneous LKB1
expression and 8-oxo-dGuo levels in human lung Ad-SCC
specimens (Figure 2C). LKB1 expression was inversely corre-
lated with 8-oxo-dGuo level in the adenomatous components
(PCC = 0.74, p < 0.001), but not the squamous components
of human Ad-SCC (PCC = 0.25, p = 0.29) (Figure 2D). Impor-
tantly, LKB1 expression was not detected in six of 19 Ad-
SCC specimens (Figure 2D). In five of the six specimens, the
8-oxo-dGuo level was higher in the adenomatous components
(Figure 2E), whereas NQO1 expression was conversely higher
in the squamous components (Figure 2F). In two such Ad-
SCC specimens, we found the expression of p63 and TTF1 in
both adenomatous and squamous components (Figures 2G
and S2F).
We further detected the expression of p63, LKB1, and TTF1
in TMAs containing 154 human lung SCC specimens. We found700 Cancer Cell 27, 698–711, May 11, 2015 ª2015 Elsevier Inc.that approximately 97.4% (150/154) of
human SCC expressed p63 but not
TTF1. LKB1 expression was not de-
tected in 37.6% (58/154) of these SCC.
Notably, only among the 58 SCC with
undetectable LKB1 expression, we
found four (6.9%) that expressed the
ADC marker TTF1 (Figure S2G). This
finding was consistent with others
showing that approximately 3% (4/115)
human SCC expressed TTF1 (Rekhtman
et al., 2011).
Collectively, these data from mouse
tumors and clinical sample analyses sug-
gest a potential association of LKB1downregulation with ROS accumulation and lung tumor
plasticity.
Alleviation of ROS Inhibits AST in KL Model
We asked whether ROS can modulate lung tumor plasticity
in KL model. We have successfully established the primary
cell line from mouse KL ADC. These cells maintained represen-
tative epithelial cell morphology in culture and typical adeno-
matous pathology without p63 expression in nude mice (Fig-
ure S3A). Upon glucose deprivation, an experimental culture
condition to mimic nutrient limitation and ROS accumulation
(Jeon et al., 2012), the KL cells were more sensitive than KP
cells to undergo cell death (Figure S3B). The cell death was
largely rescued by the treatment with the ROS scavenger
N-acetyl cysteine (NAC) (Figure S3C). Meanwhile, knockdown
of LKB1 in KP cells, which resulted in impaired downstream
pathway activity (pAMPK and pACC), promoted ROS accumu-
lation and cell death upon glucose deprivation (Figures S3D
and S3E).
To explore whether ROS alleviation affects AST, we performed
tumor analysis in Ad-Cre-infected KL mice after 4-week NAC
treatment. Interestingly, NAC treatment dramatically decreased
the SCC incidence (Figures 3A and 3B). NAC treatment also
significantly decreased the number of SCC and increased that
Figure 2. Redox and Tumor Heterogeneity
in Human NSCLC with LKB1 Deficiency
(A) IHC staining for TTF1, p63, 8-oxo-dGuo, and
LKB1 in human lung ADC. Scale bar represents
50 mm.
(B) H&E and IHC staining of TTF1, p63, and K14 on
serial sections of human lung ADC with LKB1
mutation. Scale bar represents 50 mm.
(C) Heterogeneous levels of LKB1 expression and
8-oxo-dGuo in the adenomatous component and
squamous component of human lung Ad-SCC.
Scale bar represents 50 mm.
(D) Pearson correlation coefficient (PCC) analysis
of LKB1 expression level and 8-oxo-dGuo level in
the adenomatous components and squamous
components of human lung Ad-SCC. The six
human lung Ad-SCC specimens without LKB1
expression were numbered in red on x axis.
(E) Representative IHC staining for LKB1 and
8-oxo-dGuo in the adenomatous component and
squamous component of human lung Ad-SCC.
Scale bar represents 50 mm.
(F) Representative IHC staining of p63 and NQO1
on serial sections from human lung Ad-SCC.
AC, adenomatous component; SC, squamous
component. Scale bar represents 50 mm.
(G) Representative IHC staining of p63 in the
adenomatous component and squamous com-
ponent of human lung Ad-SCC. Scale bar repre-
sents 50 mm.
See also Figure S2.of ADC (Figure 3C). The SCC from both control and NAC treat-
ment groups expressed p63 and TTF1 (Figure S3F). In addition,
we detected lower 8-oxo-dGuo level in NAC-treated ADC
(Figure 3D).
The Ad5-SPC-Cre adenovirus has been shown to efficiently
and specifically target Cre recombinase to alveolar type 2
epithelial (SPC-expressing) cells (Perl et al., 2002; Sutherland
et al., 2011; Sutherland et al., 2014). Upon Ad5-SPC-Cre infec-
tion in KL mice, we observed SCC and mixed Ad-SCC in 40%–
60% of these mice; these SCC and squamous components of
mixed Ad-SCC expressed both p63 and TTF1 (Figure S3G),
further supporting the AST in KL model. To validate that NAC
treatment inhibited AST, we performed 4-week NAC treatment
on Ad5-SPC-Cre-infected KL mice. NAC treatment decreased
the incidence and number of SCC expressing ADC marker
TTF1 and increased the ADC number (Figures 3E, 3F, S3H,Cancer Cell 27, 698–and S3I). These results collectively sug-
gest that NAC treatment inhibited AST in
the KL model.
We found that ADC had less nuclear
NRF2 expression than SCC in KL model
(Figures S1I and S3J). In KL cells, NRF2
overexpression increased the expres-
sion its targets and alleviated glucose
deprivation-elicited ROS accumulation
as well as cell death (Figures S3K and
S3L). We wondered whether ROS allevi-
ation by activating NRF2-dependent
antioxidant program mimics NAC toinhibit AST. Following an established protocol (Han et al.,
2014), the KL mice were treated via nasal inhalation with lenti-
virus expressing Cre recombinase (Lenti-Cre) with or without
NRF2, and tumor analysis was performed when the mice
from both groups (Cre and Nrf2-Cre) reached comparable
tumor burden (Figure S3M). We found that NRF2 overexpres-
sion promoted NQO1 expression and dramatically decreased
SCC incidence (Figures 3G, 3H, and S3N). NRF2 overexpres-
sion also significantly decreased the SCC number and
increased the ADC number, indicative of impaired AST (Fig-
ure 3I). Indeed, the SCC from both groups remained positive
for the ADC marker TTF1 (Figure S3O). As expected, NRF2
overexpression effectively lowered the oxidative stress in
ADC, as revealed by decreased level 8-oxo-dGuo level (Fig-
ure 3J). Together, our data indicate that ROS can functionally
modulate the tumor plasticity in KL model.711, May 11, 2015 ª2015 Elsevier Inc. 701
Figure 3. ROS Alleviation Inhibits AST in KL Model
(A and B) Representative H&E staining of lung tumor sections (A) and statistical analysis of SCC incidence (B) in saline (n = 15) and NAC (n = 15) groups of Ad-Cre-
infected KL mice (10 weeks post Ad-Cre infection). The boxed areas on the left images of (A) were magnified and shown on the right. Scale bar represents 2 mm
(left), 50 mm (right).
(C) Statistical analysis of average tumor number in saline (n = 15) and NAC (n = 15) groups of Ad-Cre-infected KLmice. Data are shown asmean ± SEM. **p < 0.01,
*p < 0.05.
(D) Representative IHC staining and statistical analysis of 8-oxo-dGuo+ cells in ADC of Ad-Cre-infected KL mice from saline and NAC groups. Scale bar rep-
resents 50 mm. Data are shown as mean ± SEM. ***p < 0.001.
(E and F) Statistical analyses of SCC incidence (E) and average tumor number (F) of Ad5-SPC-Cre-infected KL mice in saline (n = 14) and NAC (n = 14) groups.
NAC treatment was initiated at 11 weeks post Ad5-SPC-Cre infection. Data are shown as mean ± SEM. *p < 0.05.
(G and H) Representative H&E staining of mouse lung tumor sections (G) and statistical analysis of SCC incidence (H) in Cre (n = 15) and Nrf2-Cre (n = 16)
groups. The arrowhead indicates SCC. The boxed areas on the left of (G) were magnified and shown on the right. Scale bar represents 2 mm (left), 50 mm
(right).
(I) Statistical analysis of average tumor number in Cre (n = 15) and Nrf2-Cre (n = 16) groups. Data are shown as mean ± SEM. **p < 0.01, *p < 0.05.
(J) Representative IHC staining and statistical analysis of 8-oxo-dGuo+ cells in ADC of Cre and Nrf2-Cre groups. Scale bar represents 50 mm. Data are shown as
mean ± SEM. ***p < 0.001.
See also Figure S3.
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Pentose Phosphate Pathway Functionally Modulates
AST in KL Model
The pentose phosphate pathway (PPP) acts as the major source
of cellular NADPH for redox homeostasis and generates ribose
5-phosphate, the substrate of nucleotide synthesis essential for
anabolic metabolism (Cairns et al., 2011; Ward and Thompson,
2012). KL SCC was enriched for gene sets of purine metabolism
and pyrimidine metabolism (Figures 4A and 4B), correlating with
enhanced cell cycle progression and DNA replication (Fig-
ure S4A). The heatmap and qRT-PCR validation results further
revealed lower expression of most PPP signature genes in
KL ADC than SCC (Figures 4C, 4D, and S4B). Among them,
glucose-6-phosphate dehydrogenase (G6PD), the first rate-
limiting enzyme of PPP, showed lower enzymatic activity and
protein level in KL ADC than SCC (Figures 4E and S4C).
Compared to KL ADC, KP ADC not only expressed higher levels
of G6PD and PPP signature genes, but also was enriched for
gene sets of pyrimidine metabolism (Figures S4C–S4E). The
KL ADC, however, was enriched for gene sets of extracellular
matrix (ECM)-receptor interaction and cell adhesion as
compared to either KP ADC or KL SCC (Figure S4F and Table
S4). Given the observation of higher ROS level in KL ADC
than SCC, the lower PPP signatures indicate potential PPP
deregulation in KL ADC.
Because G6PD can regulate PPP activity and cellular redox
status (Cairns et al., 2011; Salvemini et al., 1999; Ward and
Thompson, 2012), we modulated G6PD expression to investi-
gate whether PPP affects AST. In KL cells, G6PD overexpres-
sion significantly decreased the ROS level (Figure S4G). Upon
lentiviral overexpression in vivo, the SCC number and incidence
decreased while ADC number increased dramatically in G6pd-
Cre group, as compared to Cre control group despite of compa-
rable tumor burden (Figures 4F–4H and S4H). Consistent with
its oncogenic role in early transformation (Kuo et al., 2000),
G6PD overexpression promoted cell proliferation in ADC (Fig-
ure S4I). Again, the SCC from both groups expressed TTF1,
the ADC marker (Figure S4J). As expected, G6PD overexpres-
sion effectively alleviated the oxidative stress in vivo (Figures
4I and S4I).
We further investigated whether decreased G6PD expression
promotes AST. In KL cells, G6PD knockdown not only increased
the ROS level and inhibited cell growth (Figures S4K and S4L),
but also upregulated several SCC signature genes (Figure S4M).
Accordingly, lentiviral G6PD knockdown in vivo increased the
incidence of SCC in a time course-dependent manner (Figures
4J and 4K). The ADC number in G6PD knockdown (shG6pd-
Cre) group decreased significantly, correlating with increased
oxidative stress and apoptosis (Figures 4L and S4N). Notably,
the SCC number increased conversely, and the SCC expressed
TTF1 (Figures 4L and 4M), indicating the accelerated squamous
transdifferentiation from certain ADCdespite of impaired growth.
Indeed, apart from p63+TTF1+ SCC, we observed TTF1+ ADC
expressing p63 in 60% of mice in G6PD-knockdown group but
not the shLuciferase-Cre (shLuci-Cre) control group (Figure 4M).
The AMPK-ACC-FAO Axis Functionally Modulates AST
in KL Model
AMPK is known as a nutrient and energy sensor that maintains
metabolic and redox homeostasis under stress (Hardie et al.,2012; Jeon et al., 2012). Consistent with inactivation of AMPK
in mouse models with Lkb1 deletion (Huang et al., 2008; Mukho-
padhyay et al., 2014; Shackelford et al., 2013), phosphorylated
AMPK (pAMPK) was undetectable in KL tumors but evident in
KP ADC (Figure 5A). We hypothesized that inactivation of energy
sensor AMPK may also contribute to ROS accumulation in KL
ADC. We thus tested the effect of AMPK re-activation upon
AST by expressing the constitutively active AMPK mutant
(caAMPK) (Foretz et al., 2005). In vitro assays showed that
caAMPK expression rescued glucose deprivation-induced cell
death by lowering the ROS level in KL cells (Figures S5A
and S5B). Upon lentiviral expression in vivo, the SCC number
and incidence in caAMPK expression group (caAMPK-Cre)
decreased as compared to Cre control group with comparable
tumor burden (Figures 5B–5D and S5B). Again, TTF1 expression
was detectable in these p63+ SCC from both groups (Fig-
ure S5C). As expected, caAMPK expression was active and
efficiently decreased the 8-oxo-dGuo levels in ADC (Figures 5E
and 5F).
We then explored AMPK downstream effectors. Because
mTORC1 is a major effector of the LKB1-AMPK energy stress
response (Shackelford and Shaw, 2009), we treated Ad-Cre-
infected KL mice with rapamycin (mTORC1 inhibitor) and
performed tumor analysis. Intriguingly, inhibition of mTORC1
signaling, as revealed by decreased rS6 phosphorylation
(pS6) (Figure S5D), significantly reduced the number of ADC
but not TTF1+ SCC (Figures S5E–S5G). Further western blotting
analyses revealed higher levels of mTORC2 target phospho-
AKT (Ser 473) in rapamycin-treated tumors (Figure S5D), sug-
gesting that certain ADC may escape rapamycin treatment
through previously reported feedback activation of Akt signaling
(Wan et al., 2007). Indeed, we further found that rapamycin
treatment on Ad5-SPC-Cre-infected KL mice decreased the
ADC number but had marginal effects upon the SCC number
(Figure S5H). Inactivation of LKB1-AMPK axis also leads to de-
regulated autophagy in lung tumors (Shackelford et al., 2013).
We crossed the autophagy-related gene 5 (Atg5) conditional
knockout (Atg5lox/lox) mice with KL mice to study whether auto-
phagy deregulation affects AST. Comparing to KL lung tumors,
the KrasG12D;Lkb1lox/lox;Atg5lox/lox (KLA) lung tumors displayed
stronger autophagy defects as indicated by the accumulation
of LC3 or p62 aggregates (Figure S5I). However, the number
of KLA ADC or SCC remained comparable to that in KL model
with similar tumor burden (Figure S5J), and the KLA SCC also
expressed TTF1 (Figure S5K). Together, these results suggest
that other AMPK effectors than mTORC1 signaling and auto-
phagy may act to modulate AST.
Under limited glucose supply when PPP is deregulated, the
major source of reducing equivalents for ROS clearance is sup-
ported by fatty acid oxidation (FAO) that is activated by the
AMPK-ACC axis (Jeon et al., 2012; Schafer et al., 2009). Notably,
the AMPK-ACC axis was impaired in KL tumors, and recovered
upon caAMPK expression (Figures 5A and 5E). We found that KL
ADC showed significantly lower enzymatic activity for key FAO
enzymes than SCC, such as carnitine palmitoytransferase 1
(CPT1) and acyl-coenzyme A synthetase (ACS) (Figure 5G).
Additionally, KL ADC not only expressed lower levels of CPT1A
and several other FAO signature genes (Figures S5L and S5M),
but also accumulated more lipids than SCC (Figure S5N). TheseCancer Cell 27, 698–711, May 11, 2015 ª2015 Elsevier Inc. 703
Figure 4. PPP Functionally Modulates AST in KL Model
(A and B) GSEA plots for purine metabolism (A) and pyrimidine metabolism (B) in KL ADC as compared to KL SCC.
(C and D) A brief scheme of pentose phosphate pathway (C) and a heatmap of PPP signature gene expression in KL ADC and SCC (D).
(legend continued on next page)
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lines of evidences indicate that impaired FAO due to inactivation
of AMPK-ACC axis may further promote ROS accumulation and
facilitates AST. Because ectopic expression of CPT1 family
member is sufficient to enhance FAO (Bruce et al., 2009; Zaugg
et al., 2011), we performed lentiviral CPT1A overexpression in KL
tumors to functionally validate this notion (Figure S5O). Conse-
quently, with comparable tumor progression to Cre control
group (Figure S5P), CPT1A overexpression did mimic caAMPK
to inhibit AST, as evidenced by the decreased incidence and
number of TTF1+p63+ SCC together with increased number of
ADC in the Cpt1a-Cre group (Figures 5H, 5I, and S5Q).
Signatures of FAO and PPP in Human ADC and Ad-SCC
with LKB1 Inactivation
We comparatively analyzed the levels of LKB1, pAMPK, and
pACC in human ADC TMAs and found significant correlations
among each of them (Figures 6A, 6B, and S6A). Consistent
with undetectable LKB1 expression, pAMPK and pACC were
not detected in the eight human ADC specimens with SCC
signature and four human SCC specimens with ADC marker
TTF1 expression (Figures S6B and S6C). In the two LKB1mutant
human ADC with SCC signature, the AMPK-ACC axis was also
inactivated (Figure 6C), and the p63+ cells expressed higher
levels of G6PD and CPT1A than adjacent TTF1+ cells (Figure 6D).
Moreover, in the four human Ad-SCC without LKB1 expression,
although the AMPK-ACC axis was inactivated in both adenoma-
tous and squamous components, the latter consistently showed
higher expression levels of G6PD and CPT1A (Figures 6E and
S6D). Based on the findings in KL mouse lung tumors, these
results thus suggest a correlation of differential PPP and FAO
signatures with the pathological heterogeneity in a subset of
human ADC and Ad-SCC with LKB1 inactivation.
The ROS-Inducing Agent Piperlongumine Promotes AST
in KL Model
We then asked whether the KL lung tumor plasticity affects drug
response to certain preclinical ROS-inducing agents. Among
several ROS-inducing agents (Raj et al., 2011; Trachootham
et al., 2009), piperlongumine (PL) was most effective to promote
apoptosis in LKB1-deficient cancer cell lines (Figures S7A and
S7B). Upon treatment on Ad-Cre-infected KL mice for 3 weeks
(Figure 7A), PL significantly decreased the ADC number (Figures
7B and 7C). Indeed, PL treatment inhibited cell proliferation and
promoted apoptosis in ADC, whereas these two parameters
remained marginally affected in SCC (Figures 7D, 7E, and
S7C), indicating the pathology-specific drug response. As
expected, PL dramatically increased the oxidative stress in KL(E) Statistical analysis of G6PDH enzymatic activity in KL ADC (n = 9) and SCC (
(F–H) Representative H&E staining of lung tumor sections (F), statistical analysis o
and G6pd-Cre (n = 15) groups. Scale bar represents 1 mm. Data are shown as m
(I) Statistical analysis of 8-oxo-dGuo+ cells in ADC from Cre and G6pd-Cre grou
(J and K) Representative H&E staining of lung tumor sections (J) and statistical a
8 weeks, n = 8 for 10 weeks) and shG6pd-Cre group (n = 10 for 8 weeks, n = 6
represents 2 mm.
(L) Statistical analysis of average number of ADC and SCC in shLuci-Cre (n = 10) a
as mean ± SEM. **p < 0.01, *p < 0.05.
(M) Representative TTF1 and p63 IHC staining on mouse ADC and SCC from the
50 mm; red scale bar represents 5 mm.
See also Figure S4 and Table S4.tumors (Figure S7D). Importantly, PL treatment also increased
the number and incidence of SCC (Figures 7C and 7F), and
the SCC expressed TTF1 (Figure S7E). Furthermore, TTF1+
ADC expressing p63 was also found in PL but not the vehicle
group (Figure 7G). These observations indicate the accelerated
squamous transdifferentiation from certain ADC despite of
overall regression by PL treatment. In support of this, we further
performed PL treatment on Ad5-SPC-Cre-infected KL mice
(Figure 7H). Consistently, although PL dramatically decreased
the ADC number, it did increase the number and incidence of
TTF1+ SCC (Figures 7I, S7F, and S7G) and promoted the occur-
rence of TTF1+ ADC expressing p63 (Figure S7G).
KL ADC Escapes Phenformin Treatment through
Squamous Transdifferentiation
Themetabolic drug phenformin as a single agent showed certain
therapeutic potential in a recent preclinical trial on KL model, but
drug resistance eventually developed with yet unknown mecha-
nisms (Hardie, 2013; Shackelford et al., 2013). Phenformin can
inhibit mitochondrial function and induce metabolic stress
(Shackelford et al., 2013). Given that phenformin efficiently
induced ROS in LKB1-deficient cancer cell lines (Figure S8A),
we reasoned that KL tumor plasticity and heterogeneity might
affect phenformin’s therapeutic response. To verify this, we per-
formed phenformin treatment on Ad-Cre-infected KL mice as
previously described (Shackelford et al., 2013). We found that
phenformin treatment significantly decreased the ADC number
(Figures 8A and 8B). Although phenformin did not significantly
affect cell proliferation in these tumors (Figures 8C and S8B), it
did selectively promoted apoptosis in ADC (Figures 8D and
S8C), and also increased oxidative stress in both tumor subtypes
(Figure S8D). However, the SCC still maintained a much higher
proliferation rate than ADC, and the apoptosis was not signifi-
cantly affected by phenformin treatment (Figures 8C, 8D, S8B,
and S8C). Importantly, the SCC number and incidence was
increased by phenformin treatment (Figures 8B and 8E), and
the SCC remained positive for TTF1 (Figure 8F). Accordingly,
phenformin treatment also promoted the occurrence of TTF1+
ADC expressing SCC markers (Figures 8G and S8E), indicative
of enhanced AST. To validate that phenformin promoted AST
through ROS accumulation, we treated Ad-Cre-infected KL
mice with phenformin with or without NAC. Indeed, combined
phenformin and NAC treatment decreased the SCC incidence
and increased the ADC number as compared to phenformin
treatment (Figure S8F).
In Ad5-SPC-Cre-infected KL mice, we further found that
phenformin treatment led to an increased incidence and numbern = 5) tissues. Data are shown as mean ± SEM. *p < 0.05.
f average tumor number (G), and SCC incidence (H) in KLmice from Cre (n = 12)
ean ± SEM. **p < 0.01, *p < 0.05.
ps. Data are shown as mean ± SEM. ***p < 0.001.
nalysis of SCC incidence (K) in KL mice of shLuci-Cre control group (n = 10 for
for 10 weeks). ShG6pd-1 was used for in vivo G6PD knockdown. Scale bar
nd shG6pd-Cre (n = 10) groups at 8 weeks post-viral infection. Data are shown
shG6pd-Cre group at 8 weeks post viral infection. Black scale bar represents
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Figure 5. The AMPK-ACC-FAO Axis Functionally Modulates AST in KL Model
(A) Representative IHC staining of pAMPK and pACC in KP ADC, KL ADC, and KL SCC. Scale bar represents 50 mm.
(B–D) Representative H&E staining of lung tumor sections (B), statistical analysis of SCC incidence (C) and average tumor number (D) in KLmice of Cre (n = 14) and
caAMPK-Cre (n = 21) groups. The arrowhead in (B) indicates SCC, and the asterisk indicates ADC. The boxed areas on the left of (B) weremagnified and shown on
the right. Scale bar represents 2 mm (left), 50 mm (right). Data are shown as mean ± SEM. *p < 0.05.
(E) Representative IHC staining of pAMPK and pACC in themouse lung tumor sections of the Cre and caAMPK-Cre groups. Black scale bar represents 50 mm; red
scale bar represents 5 mm.
(F) Representative IHC staining and statistical analysis of 8-oxo-dGuo+ cells in ADC of Cre and caAMPK-Cre groups. Scale bar represents 50 mm. Data are shown
as mean ± SEM. ***p < 0.001.
(legend continued on next page)
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Figure 6. PPPandFAOSignatures inHuman
ADC and Ad-SCC with LKB1 Inactivation
(A and B) Representative IHC staining for LKB1,
pAMPK, and pACC on serial sections of human
lung ADC TMAs (A) and Kendall’s tau correlation
analysis of the IHC staining results for LKB1,
pAMPK, or pACC in human lung ADC TMAs (B).
Scale bar represents 50 mm.
(C) Representative IHC staining for LKB1, pAMPK,
and pACC on serial sections of human lung ADC
with LKB1mutations. Scale bar represents 50 mm.
(D) Representative IHC staining for TTF1, p63,
G6PD, and CPT1A on serial sections of human
lung ADC with LKB1 mutations. Scale bar repre-
sents 50 mm.
(E) Representative IHC staining for p63, pAMPK,
pACC, and G6PD on serial sections of human Ad-
SCC without LKB1 expression. AC, adenomatous
component; SC, squamous component. Scale bar
represents 50 mm.
See also Figure S6.of TTF1+ SCC, as well as occurrence of ADC expressing
p63, although the ADC number was decreased (Figures 8H,
S8G, and S8H). Meanwhile, in vitro phenformin treatment of
mouse KL cells or the human A549 lung cancer cell line not
only increased the expression of p63 and other SCC signature
genes (Krt5 and Krt14), but also upregulated potential p63 up-
stream regulators (Klf5 and Dlx5) (Han et al., 2014) (Figures 8I(G) Statistical analysis of ACS and CPT1 enzymatic activities in KL ADC (n = 9) and SCC (n = 5). Data are sh
(H) Representative H&E staining ofmouse lung tumor sections and statistical analysis of SCC incidence fromC
represents 2 mm.
(I) Statistical analysis of the average number of SCC and ADC in Cre (n = 12) and Cpt1a-Cre (n = 14) groups
See also Figure S5.
Cancer Cell 27, 698–and S8I). Collectively, our results suggest
that phenformin treatment on KL lung tu-
mors may encounter drug resistance
potentially due to AST.
DISCUSSION
Here we show that inactivation of LKB1,
the tumor suppressor involved in cellular
energy homeostasis, elicits tumor plas-
ticity to coordinate lung tumor progres-
sion with metabolic adaptation. Together
with our previous studies (Gao et al.,
2010b; Han et al., 2014; Ji et al., 2007),
the data indicate that LKB1 may act as
a tumor suppressor at early lung ADC
progression and as an essential meta-
bolic regulator at late phenotypic transi-
tion. Our data support that ROS accumu-
lation in KL ADC may be derived from the
redox imbalance involving ROS genera-
tion by PPP deregulation and impaired
ROS alleviation due to defective activa-
tion of FAO downstream of the AMPK-
ACC axis (Figure 8J). Given the differen-tial ECM signatures between KL ADC and SCC (Han et al.,
2014), PPP deregulation can be attributed to the nutrient limita-
tion during ECM remodeling. The KL SCC, however, has lower
ROS level and higher metabolic signatures, potentially through
AMPK-independent metabolic reprogramming. Because ROS
can functionally modulate AST, it is possible that aberrant ROS
accumulation in the context of LKB1 inactivation eventuallyown as mean ± SEM. *p < 0.05.
re (n = 12) andCpt1a-Cre (n = 14) groups. Scale bar
. Data are shown as mean ± SEM. *p < 0.05.
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Figure 7. The ROS-Inducing Agent Piper-
longumine Promotes AST in KL Model
(A) A scheme of PL treatment. The KL mice at
5 weeks post Ad-Cre infection were treated with
vehicle or PL for 3 weeks, followed by tumor
analysis.
(B and C) Representative H&E staining of mouse
lung tumor sections (A) and statistical analysis of
average tumor number (C) from vehicle (n = 10)
and PL (n = 9) groups in Ad-Cre-infected KL mice.
Scale bar represents 2 mm. Data are shown as
mean ± SEM. *p < 0.05.
(D and E) Statistical analysis of the percentage
of Ki67+ cells (D) and Caspase 3+ cells (E) in the
lung tumors of vehicle and PL groups in Ad-Cre-
infected KLmice. Data are shown asmean ± SEM.
**p < 0.01, *p < 0.05.
(F) Statistical analysis of SCC incidence in the
vehicle (n = 10) or PL (n = 9) groups in Ad-Cre-
infected KL mice.
(G) Representative H&E staining and IHC staining
for TTF1 and p63 in mouse lung tumor serial
sections from the PL treatment group in Ad-Cre-
infected KL mice. Scale bar represents 50 mm.
(H) A scheme of PL treatment on Ad5-SPC-Cre-
infected KL mice. The KL mice at 12 weeks post
Ad5-SPC-Cre infection were treated with vehicle
or PL for 3 weeks, followed by tumor analysis.
(I) Statistical analysis of average tumor number
and SCC incidence in Ad5-SPC-Cre-infected KL
mice from the vehicle (n = 10) and PL (n = 12)
groups. Data are shown as mean ± SEM. **p <
0.01, *p < 0.05.
See also Figure S7.confers certain ADCwith plasticity toward squamous transdiffer-
entiation to coordinate progression with metabolic adaptation.
Compared with KL ADC, KP ADC has less ROS and does not un-
dergo squamous transdifferentiation, at least partly due to the
intact metabolic regulatory axis by LKB1. In line with this, we
have found that deletion of Lkb1 in KP model resulted in an
impaired AMPK-ACC axis and promoted ROS accumulation as
well as squamous transdifferentiation from ADC (data not
shown). These findings reinforce LKB1 as an essential regulator
of metabolic homeostasis, and the oxidative stress as a poten-
tially specific progression checkpoint for KL ADC in vivo.
Because ROS regulates diverse signal transduction and gene
expression (D’Autre´aux and Toledano, 2007) and LKB1 also reg-
ulates other pathways and biological processes (Gao et al.,
2014; Mohseni et al., 2014; Shackelford and Shaw, 2009), it re-
mains to be investigated how ROS acts and potentially syner-
gizes with other cross-talking mechanisms in context of LKB1
inactivation to modulate AST.
In accordance with previous studies showing the promise to
target cancer metabolism for therapy (Raj et al., 2011; Shackel-
ford et al., 2013; Tennant et al., 2010), we find that the ROS-
inducing agent piperlongumine and metabolic drug phenformin
do show therapeutic effects upon ADC in preclinical trials on
KL model. However, these therapeutic effects seem less effec-
tive upon KL SCC, consistent with the differential redox and
metabolic signatures. Importantly, PL or phenformin treatment
accelerates squamous transdifferentiation from certain ADC.
Because the SCC has a higher cell proliferation rate and lower708 Cancer Cell 27, 698–711, May 11, 2015 ª2015 Elsevier Inc.drug sensitivity, the AST process may eventually lead to drug
resistance as a potentially important mechanism. This transition
also supports the notion that tumor plasticity and heterogeneity
contribute to therapeutic resistance and disease progression
(Haq et al., 2013; O’Connell et al., 2013; Vazquez et al., 2013).
Emerging evidences have uncovered the plastic and heteroge-
neous nature of NSCLC in clinic (Chen et al., 2014; Heist and En-
gelman, 2012). Here we find that certain human lung ADC with
LKB1 inactivation indeed express a SCC signature, and human
lung SCC with LKB1 inactivation can also express ADC marker
TTF1. Moreover, ADC and SCC lineage markers (TTF1 and p63)
are expressed in both adenomatous and squamous components
of certain LKB1-inactivated Ad-SCC. Importantly, the patholog-
ical and redox heterogeneity from these clinical specimens are
consistent with our findings from KL mouse lung tumors with
strong plasticity. Although validation of squamous transdifferen-
tiation from human lung ADC is challenging, it is tempting to
speculate that the redox imbalance may serve as one important
metabolic modifier of tumor plasticity in certain patients with
NSCLC with LKB1 inactivation, and the tumor plasticity in turn
may predict drug response and clinical outcome, especially for
therapy directed at cancer metabolism.EXPERIMENTAL PROCEDURES
Mouse Colony, Mouse Treatment, and Tumor Analyses
KrasG12D, Lkb1lox/lox, and Trp53 lox/lox mice were originally generously pro-
vided by T. Jacks, R. Depinho, and D.J. Kwiatkowski, respectively (Bardeesy
Figure 8. Phenformin Promotes AST in KL
Model
(A and B) Representative H&E staining of lung
tumor sections (A) and statistical analysis of
average tumor number (B) in the control (n = 11)
and phenformin (n = 9) groups of Ad-SPC-Cre-
infected KLmice. Scale bar represents 2mm.Data
are shown as mean ± SEM. *p < 0.05.
(C) Statistical analysis on the percentage of Ki67+
cells in the lung tumors of Ad-Cre-infected KL
mice from control and phenformin groups. Data
are shown as mean ± SEM.
(D) Statistical analysis of the percentage of
Caspase 3+ cells in the lung tumors from control
and phenformin groups of Ad-Cre-infected KL
mice. Data are shown as mean ± SEM. **p < 0.01,
*p < 0.05.
(E) Statistical analysis of SCC incidence in Ad-Cre-
infected KL mice of the control (n = 11) and
phenformin (n = 9) groups.
(F) Representative IHC staining for p63 and
TTF1 in SCC of Ad-Cre-infected KL mice from
the phenformin group. Black scale bar repre-
sents 50 mm; red scale bar represents 10 mm.
(G) Representative H&E staining and IHC stain-
ing for p63 and TTF1 in ADC of Ad-Cre-infected
KL mice from phenformin group. Black scale bar
represents 100 mm (left), 50 mm (right); red scale
bar represents 10 mm.
(H) Statistical analysis of SCC incidence and
average tumor number in Ad5-SPC-Cre-in-
fected KL mice of the control (n = 10) and
phenformin (n = 14) groups. Phenformin treat-
ment was initiated at 12 weeks post-Ad5-SPC-
Cre infection. Data are shown as mean ± SEM.
**p < 0.01, *p < 0.05.
(I) qRT-PCR analysis of relative expression for
the indicated genes in mouse KL cells treated
with phenformin (0–5 mM) for 24 hr. Represen-
tative data were shown from three independent
experiments. Data are shown as mean ± SEM.
***p < 0.001, **p < 0.01, *p < 0.05.
(J) A scheme of dynamic role for LKB1 inacti-
vation in NSCLC of KL model.
See also Figure S8.et al., 2002; Jackson et al., 2001; Liang et al., 2010; Tuveson and Jacks,
1999). Atg5lox/lox mice were provided by the RIKEN BRC through the National
Bio-Resource Project of the MEXT, Japan (Hara et al., 2006). Mouse care and
treatmentwas approved by theAnimalCare andUseCommittee at the Institute
of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences,
Chinese Academy of Sciences. Mice were treated via nasal inhalation of
adenovirus or lentivirus carrying Cre recombinase (2 3 106 p.f.u for Ad-Cre
and Lenti-Cre, 1 3 106 p.f.u for Ad5-SPC-Cre) as described (DuPage et al.,
2009; Gao et al., 2010b; Han et al., 2014; Sutherland et al., 2011). To exclude
the potential impact of tumor progression upon AST as previously (Han et al.,
2014), the lentivirus-infected KL mice with NRF2, G6PD, caAMPK, or CPT1A
overexpression were analyzed for AST when they reached comparable tumor
progression at 10–13 weeks post-treatment (Cre, 10 weeks; Nrf2-Cre,
13 weeks; G6pd-Cre, 10 weeks; caAMPK-Cre, 13 weeks; and Cpt1a-Cre,
11 weeks). Where indicated, Ad-Cre-infected or Ad5-SPC-Cre-infected KL
mice were treated with vehicle or piperlongumine (Sigma, 1.5 mg/kg/day)
through intraperitoneal (i.p.) injection as previously done (Raj et al., 2011; Vaz-
quez et al., 2013). Phenformin (Sigma) was administrated ad lib in drinkingwater (1.8 mg/ml) and changed every other day (Shackelford et al., 2013).
Rapamycin (1.5 mg/kg) or NAC (100 mg/kg) was administrated through i.p. in-
jection. Mice were then killed at indicated times for gross inspection and
histopathological examination. Tumor burden, average tumor size, and tumor
number were determined through Photoshop (Adobe) and Image J (NIH) as
described elsewhere (Gao et al., 2010b; Han et al., 2014).
Human Lung Cancer Specimens
Human lung ADC, SCC, and Ad-SCC specimens were collected with the
approval by the institutional review committee of Shanghai Cancer Hospital,
Fudan University, Shanghai, China as previously (Gao et al., 2010a; Sun
et al., 2010; Wang et al., 2014). All patients gave written informed consent.
All cases were re-reviewed by pathologists from the Department of Pathology
in Shanghai Cancer Hospital for confirmation of tumor histology and tumor
content. Human lung ADC and SCC TMAs were provided by the Department
of Pathology in Shanghai Cancer Hospital, Fudan University, Shanghai, China.
Where indicated, the TMAs were used for IHC staining (8-oxo-dGuo, LKB1,
TTF1, p63, K5, K14, pAMPK, and pACC) and statistical analysis.Cancer Cell 27, 698–711, May 11, 2015 ª2015 Elsevier Inc. 709
Statistical Analysis
Statistical analyses were carried out using SPSS 16.0 or GraphPad Prism 5
software. Unless indicated, differences were compared using two-tailed
Student’s t test.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
eight figures, and four tables and can be found with this article online at
http://dx.doi.org/10.1016/j.ccell.2015.04.001.
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